Replies to post #202322 on Biotech Values

[DewDiligence]

RVNC—I understand what you are saying with regards to RT002 having the best potential here and that RT001 should not have been a priority in the first place. However, I assume that the company had prioritized RT001 ahead of RT002 for reasons that are inconsistent with RT002 having better clinical potential. Why did the company do that in your view? Until I understand that, it is hard for me to be excited about anything that the company does.

RT001 was not prioritized over RT002; rather RT001 completed a phase-3 trial sooner because the development plan for RT001 was less robust. Specifically, RT001 went to phase-3 in crow’s feet without any head-to-head data vs Botox (or another botulinum toxin), while RT002 was tested vs Botox in the phase-2 BELMONT study, allowing proper dose selection for phase-3 as well as a duration-of-action comparison to Botox.

Thus, I would argue that, rather than expediting RT001, RVNC put RT002 on a more deliberate and rigorous development path, recognizing that RT002 was the more consequential asset.

Good question—thanks for asking.